Earlier this week, COMPASS Pathways announced that it has acquired an IP portfolio that seeks to cover a “variety of psychedelic and empathogenic substances, some of which are prodrugs.” The company says that the IP was developed with Matthias Grill PhD, via his company MiHKAL (presumably meaning Molecules I Have Known and Loved, in a nod to Shulgin’s seminal publications), which is based in Basel…


Previous articleAmanita muscaria – A Fresh Look at An Iconic Mushroom
Next articleBeckley Psytech announces first patient has received low-dose psilocybin in world-first clinical trial for rare headache disorder